Publications - IR Sant Pau

Search

01/01/2023 Current and Future Perspectives of Health-Related Quality of Life in Resectable EGFR-Mutated Non-Small Cell Lung Cancer: A Podcast

John T., Majem M., Legg D., Goldman J.. Current and Future Perspectives of Health-Related Quality of Life in Resectable EGFR-Mutated Non-Small Cell Lung Cancer: A Podcast. Targeted Oncology. 2023; 18(1)DOI:10.1007/s11523-022-00927-5. PMID:36534268. IF:4.400(Q2/3D).

01/01/2023 Primary endpoints to assess the efficacy of novel therapeutic approaches in epidermal growth factor receptor-mutated, surgically resectable non-small cell lung cancer: A review

Blakely C.M., Weder W., Bubendorf L., He J., Majem M., Shyr Y., Chaft J.E.. Primary endpoints to assess the efficacy of novel therapeutic approaches in epidermal growth factor receptor-mutated, surgically resectable non-small cell lung cancer: A review. LUNG CANCER. 2023; 177DOI:10.1016/j.lungcan.2023.01.002. PMID:36736076. IF:4.500(Q1/2D).

01/01/2023 Liquid Biopsy Detects Early Molecular Response and Predicts Benefit to First-Line Chemotherapy plus Cetuximab in Metastatic Colorectal Cancer: PLATFORM-B Study

Vidal J., Fernández-Rodríguez M.C., Casadevall D., García-Alfonso P., Páez D., Guix M., Alonso V., Cano M.T., Santos C., Durán G., Elez E., Manzano J.L., Garcia-Carbonero R., Ferreiro R., Losa F., Pineda E., Sastre J., Rivera F., Bellosillo B., Tabernero J., Aranda E., Salazar R., Montagut C.. Liquid Biopsy Detects Early Molecular Response and Predicts Benefit to First-Line Chemotherapy plus Cetuximab in Metastatic Colorectal Cancer: PLATFORM-B Study. CLINICAL CANCER RESEARCH. 2023; 29(2)DOI:10.1158/1078-0432.CCR-22-1696. PMID:36074154. IF:10.400(Q1/1D).

01/01/2023 Current professional standing of young medical oncologists in Spain: a nationwide survey by the Spanish Society of Medical Oncology + MIR section

Martinez D.A.S., Quilez-Cutillas A., Jimenez-Labaig P., Sesma A., Tarazona N., Pacheco-Barcia V., Obispo B., Paez D., Quintanar T., Sanchez-Canovas M., Montes A.F., Felip E., Rodriguez-Lescure A., Elez E.. Current professional standing of young medical oncologists in Spain: a nationwide survey by the Spanish Society of Medical Oncology + MIR section. Clinical & Translational Oncology. 2023; 25(3)DOI:10.1007/s12094-022-02989-3. PMID:36418642. IF:2.800(Q2/5D).

01/01/2023 Author Correction: Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer (Nature Communications, (2023), 14, 1, (1070), 10.1038/s41467-023-35961-y)

Chmielecki J., Gray J.E., Cheng Y., Ohe Y., Imamura F., Cho B.C., Lin M.-C., Majem M., Shah R., Rukazenkov Y., Todd A., Markovets A., Barrett J.C., Hartmaier R.J., Ramalingam S.S.. Author Correction: Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer (Nature Communications, (2023), 14, 1, (1070), 10.1038/s41467-023-35961-y). Nature Communications. 2023; 14(1)DOI:10.1038/s41467-023-38999-0. PMID:37263992. IF:14.700(Q1/1D).

01/01/2023 BID expression determines the apoptotic fate of cancer cells after abrogation of the spindle assembly checkpoint by AURKB or TTK inhibitors

Bertran-Alamillo J., Giménez-Capitán A., Román R., Talbot S., Whiteley R., Floc’h N., Martínez-Pérez E., Martin M.J., Smith P.D., Sullivan I., Terp M.G., Saeh J., Marino-Buslje C., Fabbri G., Guo G., Xu M., Tornador C., Aguilar-Hernández A., Reguart N., Ditzel H.J., Martínez-Bueno A., Nabau-Moretó N., Gascó A., Rosell R., Pease J.E., Polanska U.M., Travers J., Urosevic J., Molina-Vila M.A.. BID expression determines the apoptotic fate of cancer cells after abrogation of the spindle assembly checkpoint by AURKB or TTK inhibitors. Molecular Cancer. 2023; 22(1)DOI:10.1186/s12943-023-01815-w. PMID:37443114. IF:27.700(Q1/1D).

01/01/2023 Author Correction: BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer (Scientific Reports, (2015), 5, 1, (17499), 10.1038/srep17499)

Karachaliou N., Codony-Servat J., Teixidó C., Pilotto S., Drozdowskyj A., Codony-Servat C., Giménez-Capitán A., Molina-Vila M.A., Bertrán-Alamillo J., Gervais R., Massuti B., Morán T., Majem M., Felip E., Carcereny E., García-Campelo R., Viteri S., González-Cao M., Morales-Espinosa D., Verlicchi A., Crisetti E., Chaib I., Santarpia M., Luis Ramírez J., Bosch-Barrera J., Felipe Cardona A., de Marinis F., López-Vivanco G., Miguel Sánchez J., Vergnenegre A., Sánchez Hernández J.J., Sperduti I., Bria E., Rosell R.. Author Correction: BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer (Scientific Reports, (2015), 5, 1, (17499), 10.1038/srep17499). Scientific Reports. 2023; 13(1)DOI:10.1038/s41598-023-30374-9. PMID:36869103. IF:3.800(Q1/2D).

01/01/2023 Economic burden of locoregional and metastatic relapses in resectable early-stage non-small cell lung cancer in Spain

De Castro J., Insa A., Collado-Borrell R., Escudero-Vilaplana V., Martínez A., Fernandez E., Sullivan I., Arrabal N., Carcedo D., Manzaneque A.. Economic burden of locoregional and metastatic relapses in resectable early-stage non-small cell lung cancer in Spain. BMC Pulmonary Medicine. 2023; 23(1)DOI:10.1186/s12890-023-02356-0. PMID:36809990. IF:2.600(Q2/5D).

01/01/2023 Adjuvant dabrafenib and trametinib for patients with resected BRAF -mutated melanoma: DESCRIBE-AD real-world retrospective observational study

Manzano J.L., Martin-Liberal J., Fernández-Morales L.A., Benítez G., Medina Martínez J., Quindós M., García-Castaño A., Fernández O., Simo R.V., Majem M., Bellido L., Ayala de Miguel P., Campos B., Espinosa E., Macías Cerrolaza J.A., Gil-Arnaiz I., Lorente D., Rodriguez-Lescure A., Perez V.N., López Castro R., Gramaje M.G., Puértolas T., Rodriguez Moreno J.F., Espasa Font L., Belaustegui Ferrández G., Cerezuela-Fuentes P.. Adjuvant dabrafenib and trametinib for patients with resected BRAF -mutated melanoma: DESCRIBE-AD real-world retrospective observational study. MELANOMA RESEARCH. 2023; 33(5)DOI:10.1097/CMR.0000000000000888. PMID:36988401. IF:1.500(Q3/7D).

01/01/2023 Immunogenicity of COVID-19 vaccines in lung cancer patients

Provencio M., Estival A., Franco F., López-Vivanco G., Saigí M., Arasanz H., Diz P., Carcereny E., García J., Aguado C., Mosquera J., Iruarrizaga E., Majem M., Bosch-Barrera J., Mielgo-Rubio X., Guirado M., Juan-Vidal Ó., Blasco A., Lucía Gozálvez C., Del Barrio A., De Portugal T., López-Martín A., Serrano G., Campos B., Rubio J., Catot S., Esteban B., Martí-Ciriquian J.L., del Barco E., Calvo V.. Immunogenicity of COVID-19 vaccines in lung cancer patients. LUNG CANCER. 2023; 184DOI:10.1016/j.lungcan.2023.107323. PMID:37639820. IF:4.500(Q1/2D).

01/01/2023 Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer

O'Donnell P.H., Milowsky M.I., Petrylak D.P., Hoimes C.J., Flaig T.W., Mar N., Moon H.H., Friedlander T.W., McKay R.R., Bilen M.A., Srinivas S., Burgess E.F., Ramamurthy C., George S., Geynisman D.M., Bracarda S., Borchiellini D., Geoffrois L., Maroto Rey J.P., Ferrario C., Carret A.-S., Yu Y., Guseva M., Homet Moreno B., Rosenberg J.E.. Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer. JOURNAL OF CLINICAL ONCOLOGY. 2023; 41(25)DOI:10.1200/JCO.22.02887. PMID:37369081. IF:42.100(Q1/1D).

01/01/2023 Pembrolizumab as first-line treatment for advanced NSCLC in older adults: A phase II clinical trial evaluating geriatric and quality-of-life outcomes

Blanco R., Dómine M., González J.L., Loutfi S., Alfaro J., Saldaña J., Rubio J., Campos B., Hidalgo J., Barba A., Márquez D., Martin M., Olaverri A., Nadal E.. Pembrolizumab as first-line treatment for advanced NSCLC in older adults: A phase II clinical trial evaluating geriatric and quality-of-life outcomes. LUNG CANCER. 2023; 183DOI:10.1016/j.lungcan.2023.107318. PMID:37557022. IF:4.500(Q1/2D).

01/01/2023 Three-Year Safety, Tolerability, and Health-Related Quality of Life Outcomes of Adjuvant Osimertinib in Patients With Resected Stage IB to IIIA EGFR-Mutated NSCLC: Updated Analysis From the Phase 3 ADAURA Trial

John T., Grohé C., Goldman J.W., Shepherd F.A., de Marinis F., Kato T., Wang Q., Su W.-C., Choi J.H., Sriuranpong V., Melotti B., Fidler M.J., Chen J., Albayaty M., Stachowiak M., Taggart S., Wu Y.-L., Tsuboi M., Herbst R.S., Majem M.. Three-Year Safety, Tolerability, and Health-Related Quality of Life Outcomes of Adjuvant Osimertinib in Patients With Resected Stage IB to IIIA EGFR-Mutated NSCLC: Updated Analysis From the Phase 3 ADAURA Trial. Journal of Thoracic Oncology. 2023; 18(9)DOI:10.1016/j.jtho.2023.05.015. PMID:37236398. IF:21.100(Q1/1D).

01/01/2023 Adjuvant Osimertinib vs. Placebo in Completely Resected Stage IA2–IA3 EGFR-Mutated NSCLC: ADAURA2

Tsutani Y., Goldman J.W., Dacic S., Yatabe Y., Majem M., Huang X., Chen A., van der Gronde T., He J.. Adjuvant Osimertinib vs. Placebo in Completely Resected Stage IA2–IA3 EGFR-Mutated NSCLC: ADAURA2. Clinical Lung Cancer. 2023; 24(4)DOI:10.1016/j.cllc.2023.02.002. PMID:36872181. IF:3.300(Q2/4D).

01/01/2023 Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial

Herbst R.S., Wu Y.-L., John T., Grohe C., Majem M., Wang J., Kato T., Goldman J.W., Laktionov K., Kim S.-W., Yu C.-J., Vu H.V., Lu S., Lee K.Y., Mukhametshina G., Akewanlop C., De Marinis F., Bonanno L., Domine M., Shepherd F.A., Urban D., Huang X., Bolanos A., Stachowiak M., Tsuboi M.. Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial. JOURNAL OF CLINICAL ONCOLOGY. 2023; 41(10)DOI:10.1200/JCO.22.02186. PMID:36720083. IF:42.100(Q1/1D).

01/01/2023 Atezolizumab Plus Bevacizumab as First-line Treatment for Patients with Metastatic Nonsquamous Non-Small Cell Lung Cancer with High Tumor Mutation Burden: A Nonrandomized Controlled Trial

Provencio M., Ortega A.L., Coves-Sarto J., Calvo V., Marsé-Fabregat R., Dómine M., Guirado M., Carcereny E., Fernández N., Álvarez R., Blanco R., León-Mateos L., Sánchez-Torres J.M., Sullivan I.G., Cobo M., Sánchez-Hernández A., Massuti B., Sierra-Rodero B., Mártinez-Toledo C., Serna-Blasco R., Romero A., Cruz-Bermúdez A.. Atezolizumab Plus Bevacizumab as First-line Treatment for Patients with Metastatic Nonsquamous Non-Small Cell Lung Cancer with High Tumor Mutation Burden: A Nonrandomized Controlled Trial. JAMA Oncology. 2023; 9(3)DOI:10.1001/jamaoncol.2022.5959. PMID:36520426. IF:22.300(Q1/1D).

01/01/2023 Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms

Grünwald V., Powles T., Eto M., Kopyltsov E., Rha S.Y., Porta C., Motzer R., Hutson T.E., Méndez-Vidal M.J., Hong S.-H., Winquist E., Goh J.C., Maroto P., Buchler T., Takagi T., Burgents J.E., Perini R., He C., Okpara C.E., McKenzie J., Choueiri T.K.. Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms. Frontiers in Oncology. 2023; 13DOI:10.3389/fonc.2023.1223282. PMID:37664025. IF:3.500(Q2/4D).

01/01/2023 Use of concomitant proton pump inhibitors, statins or metformin in patients treated with pembrolizumab for metastatic urothelial carcinoma: data from the ARON-2 retrospective study

Fiala O., Buti S., Takeshita H., Okada Y., Massari F., Palacios G.A., Dionese M., Scagliarini S., Büttner T., Fornarini G., Myint Z.W., Galli L., Souza V.C., Pichler R., De Giorgi U., Quiroga M.N.G., Gilbert D., Popovic L., Grande E., Mammone G., Berardi R., Crabb S.J., Molina-Cerrillo J., Freitas M., Luz M., Iacovelli R., Calabrò F., Tural D., Atzori F., Küronya Z., Chiari R., Campos S., Caffo O., Fay A.P., Kucharz J., Zucali P.A., Rinck J.A., Zeppellini A., Bastos D.A., Aurilio G., Mota A., Trindade K., Ortega C., Sade J.P., Rizzo M., Vau N., Giannatempo P., Barillas A., Monteiro F.S.M., Dauster B., Cattrini C., Nogueira L., de Carvalho Fernandes R., Seront E., Aceituno L.G., Grillone F., Cutuli H.J., Fernandez M., Bassanelli M., Roviello G., Abahssain H., Procopio G., Milella M., Kopecky J., Martignetti A., Messina C., Caitano M., Inman E., Kanesvaran R., Herchenhorn D., Santini D., Manneh R., Bisonni R., Zakopoulou R., Mosca A., Morelli F., Maluf F., Soares A., Nunes F., Pinto A., Zgura A., Incorvaia L., Ansari J., Zabalza I.O., Landmesser J., Rizzo A., Mollica V., Sorgentoni G., Battelli N., Porta C., Bellmunt J., Santoni M.. Use of concomitant proton pump inhibitors, statins or metformin in patients treated with pembrolizumab for metastatic urothelial carcinoma: data from the ARON-2 retrospective study. CANCER IMMUNOLOGY IMMUNOTHERAPY. 2023; 72(11)DOI:10.1007/s00262-023-03518-z. PMID:37676282. IF:4.600(Q1/3D).

01/01/2023 Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer

Wakelee H., Liberman M., Kato T., Tsuboi M., Lee S.-H., Gao S., Chen K.-N., Dooms C., Majem M., Eigendorff E., Martinengo G.L., Bylicki O., Rodríguez-Abreu D., Chaft J.E., Novello S., Yang J., Keller S.M., Samkari A., Spicer J.D.. Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer. NEW ENGLAND JOURNAL OF MEDICINE. 2023; 389(6)DOI:10.1056/NEJMoa2302983. PMID:37272513. IF:96.300(Q1/1D).

01/01/2023 Quality of life with palbociclib plus fulvestrant versus placebo plus fulvestrant in postmenopausal women with endocrine-sensitive hormone receptor-positive and HER2-negative advanced breast cancer: patient-reported outcomes from the FLIPPER trial

Tibau A., Martínez M.T., Ramos M., De La Cruz-Merino L., Santaballa A., O’Connor M., Martínez-Jañez N., Moreno F., Fernández I., Virizuela J.A., Alarcón J., de La Haba-Rodríguez J., Sánchez-Rovira P., Albacar C.R., Bueno Muiño C., Kelly C., Casas M., Bezares S., Rosell L., Albanell J.. Quality of life with palbociclib plus fulvestrant versus placebo plus fulvestrant in postmenopausal women with endocrine-sensitive hormone receptor-positive and HER2-negative advanced breast cancer: patient-reported outcomes from the FLIPPER trial. Therapeutic Advances in Medical Oncology. 2023; 15DOI:10.1177/17588359221148921. PMID:36743520. IF:4.300(Q2/3D).

01/01/2023 The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy

Jimenez-Fonseca P., Foy V., Raby S., Carmona-Bayonas A., Macía-Rivas L., Arrazubi V., Cacho Lavin D., Hernandez San Gil R., Custodio A., Cano J.M., Fernández Montes A., Mirallas O., Macias Declara I., Vidal Tocino R., Visa L., Limón M.L., Pimentel P., Martínez Lago N., Sauri T., Martín Richard M., Mangas M., Gil Raga M., Calvo A., Reguera P., Granja M., Martín Carnicero A., Hernández Pérez C., Cerdá P., Gomez Gonzalez L., Garcia Navalon F., Pacheco Barcia V., Gutierrez Abad D., Ruiz Martín M., Weaver J., Mansoor W., Gallego J.. The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy. Therapeutic Advances in Medical Oncology. 2023; 15DOI:10.1177/17588359231157641. PMID:36895850. IF:4.300(Q2/3D).

01/01/2023 Phase II trial of CDK4/6 inhibitor palbociclib in advanced sarcoma based on mRNA expression of CDK4/ CDKN2A

Martin-Broto J., Martinez-Garcia J., Moura D.S., Redondo A., Gutierrez A., Lopez-Pousa A., Martinez-Trufero J., Sevilla I., Diaz-Beveridge R., Solis-Hernandez M.P., Carnero A., Perez M., Marcilla D., Garcia-Foncillas J., Romero P., Fernandez-Jara J., Lopez-Lopez D., Arribas I., Hindi N.. Phase II trial of CDK4/6 inhibitor palbociclib in advanced sarcoma based on mRNA expression of CDK4/ CDKN2A. Signal Transduction and Targeted Therapy. 2023; 8(1)DOI:10.1038/s41392-023-01661-8. PMID:37875500. IF:40.800(Q1/1D).

30/07/2022 Reforms to accelerated approval of new medicines: long overdue

Hwang, TJ, Trinh, QD, Tibau, A, Vokinger, KN. Reforms to accelerated approval of new medicines: long overdue. LANCET. 2022; 400(10349)DOI:10.1016/S0140-6736(22)01276-4. PMID:35835129. IF:168.900(Q1/1D).

01/06/2022 Ilixadencel, a Cell-based Immune Primer, plus Sunitinib Versus Sunitinib Alone in Metastatic Renal Cell Carcinoma: A Randomized Phase 2 Study

Lindskog, M, Laurell, A, Kjellman, A, Melichar, B, Rey, PM, Zielinski, H, Villacampa, F, Bigot, P, Zoltan, B, Parikh, O, Alba, DV, Jellvert, D, Flasko, T, Gallardo, E, Caparros, MJR, Purkalne, G, Suenaert, P, Karlsson-Parra, A, Ljungberg, B. Ilixadencel, a Cell-based Immune Primer, plus Sunitinib Versus Sunitinib Alone in Metastatic Renal Cell Carcinoma: A Randomized Phase 2 Study. European Urology Open Science. 2022; 40DOI:10.1016/j.euros.2022.03.012. PMID:35638086. IF:2.500(Q3/6D).

01/01/2022 CES1 and SLC6A2 Genetic Variants As Predictors of Response To Methylphenidate in Autism Spectrum Disorders

Hernandez, MH, Bote, V, Serra-LLovich, A, Cendros, M, Salazar, J, Mestres, C, Guijarro, S, Alvarez, A, Lamborena, C, Mendez, I, Sanchez, B, Hervas, A, Arranz, MJ. CES1 and SLC6A2 Genetic Variants As Predictors of Response To Methylphenidate in Autism Spectrum Disorders. Pharmacogenomics & Personalized Medicine. 2022; 15DOI:10.2147/PGPM.S377210. PMID:36393977. IF:1.900(Q4/9D).

01/01/2022 Association between control group therapy and magnitude of clinical benefit of cancer drugs

Molto C., Tibau A., Bujosa A., Tapia J.C., Mittal A., Tamimi F., Amir E.. Association between control group therapy and magnitude of clinical benefit of cancer drugs. Scientific Reports. 2022; 12(1)DOI:10.1038/s41598-022-25983-9. PMID:36494465. IF:(Q/D).

01/01/2022 A Paradigm Shift for Resectable Non-Small Cell Lung Cancer

Isla D., Majem M.. A Paradigm Shift for Resectable Non-Small Cell Lung Cancer. ARCHIVOS DE BRONCONEUMOLOGIA. 2022; 58(12)DOI:10.1016/j.arbres.2022.04.004. PMID:35595655. IF:8.000(Q1/2D).

01/01/2022 A randomised phase 2 study comparing different dose approaches of induction treatment of regorafenib in previously treated metastatic colorectal cancer patients (REARRANGE trial)

Argilés G., Valladares-Ayerbes M., Viéitez J.M., García-Paredes B., Rodríguez-Garrote M., Rivera F., Goldberg R.M., Ciardiello F., Tabernero J.M., Goldberg R., Argilés, Tabernero J., Mulet N., Limón M.L., Valladares M., Jiménez P., Vieitez J.M., Grávalos C., García-Alfonso P., Santos C., Páez D., Tobeña M., Sastre J., García Paredes B., Benavides M., Aranda E., Cano M.T., Loupakis F., Rguez Garrote M., Guillén C., Rivera M.F., Safont J., Hiret S., Bennouna J., Pannier D., Malka D., Falcone A., Cremolini C., The. A randomised phase 2 study comparing different dose approaches of induction treatment of regorafenib in previously treated metastatic colorectal cancer patients (REARRANGE trial). EUROPEAN JOURNAL OF CANCER. 2022; 177DOI:10.1016/j.ejca.2022.09.037. PMID:36335783. IF:8.400(Q1/2D).

01/01/2022 A phase II trial of weekly nab-paclitaxel for progressive and symptomatic desmoid tumors

Martin-Broto J., Redondo A., Moura D.S., Valverde C., Morales J.M., Lopez-Pousa A., Martinez-Trufero J., Gutierrez A., Díaz-Beveridge R., Luna P., Martinez-Marin V., Marcilla D., Arribas I., Ledesma P., Lopez-Martin J.A., Di Lernia D., Zamora J., Hindi N.. A phase II trial of weekly nab-paclitaxel for progressive and symptomatic desmoid tumors. Nature Communications. 2022; 13(1)DOI:10.1038/s41467-022-33975-6. PMID:36271011. IF:16.600(Q1/1D).

01/01/2022 Corrigendum to “SELNET clinical practice guidelines for bone sarcoma” Critical reviews in oncology/hematology, vol. 174 (2022), 1–10 (Critical Reviews in Oncology / Hematology (2022) 174, (S1040842822001093), (10.1016/j.critrevonc.2022.103685))

Blay J.Y., Palmerini E., Bollard J., Aguiar S., Angel M., Araya B., Badilla R., Bernabeu D., Campos F., Chs C.-S., Carvajal Montoya A., Casavilca-Zambrano S., Castro-Oliden, 5th, Chacón M., Clara-Altamirano M.A., Collini P., Correa Genoroso R., Costa F.D., Cuellar M., Dei Tos A.P., Dominguez Malagon H.R., Donati D.M., Dufresne A., Eriksson M., Farias-Loza M., Frezza A.M., Frisoni T., Garcia-Ortega D.Y., Gerderblom H., Gouin F., Gómez-Mateo M.C., Gronchi A., Haro J., Hindi N., Huanca L., Jimenez N., Karanian M., Kasper B., Lopes A., Lopes David B.B., Lopez-Pousa A., Lutter G., Maki R.G., Martinez-Said H., Martinez-Tlahuel J.L., Mello C.A., Morales Pérez J.M., Moura D.S., Nakagawa S.A., Nascimento A.G., Ortiz-Cruz E.J., Patel S., Pfluger Y., Provenzano S., Righi A., Rodriguez A., Santos T.G., Scotlandi K., Mlg S., Soulé T., Stacchiotti S., Valverde C.M., Waisberg F., Zamora Estrada E., Martin-Broto J.. Corrigendum to “SELNET clinical practice guidelines for bone sarcoma” Critical reviews in oncology/hematology, vol. 174 (2022), 1–10 (Critical Reviews in Oncology / Hematology (2022) 174, (S1040842822001093), (10.1016/j.critrevonc.2022.103685)). CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY. 2022; 180DOI:10.1016/j.critrevonc.2022.103827. PMID:36220678. IF:6.200(Q1/3D).

01/01/2022 Safety and efficacy of ribociclib plus letrozole in patients with HR+, HER2– advanced breast cancer: Results from the Spanish sub-population of the phase 3b CompLEEment-1 trial

Salvador Bofill J., Moreno Anton F., Rodriguez Sanchez C.A., Galve Calvo E., Hernando Melia C., Ciruelos Gil E.M., Vidal M., Jiménez-Rodriguez B., De la Cruz Merino L., Martínez Jañez N., Villanueva Vazquez R., de Toro Salas R., Anton Torres A., Alvarez Lopez I.M., Gavila Gregori J., Quiroga Garcia V., Vicente Rubio E., De la Haba-Rodriguez J., Gonzalez-Santiago S., Diaz Fernandez N., Barnadas Molins A., Cantos Sanchez de Ibargüen B., Delgado Mingorance J.I., Bellet Ezquerra M., de Casa S., Gimeno A., Martin M.. Safety and efficacy of ribociclib plus letrozole in patients with HR+, HER2– advanced breast cancer: Results from the Spanish sub-population of the phase 3b CompLEEment-1 trial. BREAST. 2022; 66DOI:10.1016/j.breast.2022.09.006. PMID:36206609. IF:3.900(Q1/3D).

01/01/2022 Considerations on diagnosis and surveillance measures of PTEN hamartoma tumor syndrome: clinical and genetic study in a series of Spanish patients

Pena-Couso L., Ercibengoa M., Mercadillo F., Gómez-Sánchez D., Inglada-Pérez L., Santos M., Lanillos J., Gutiérrez-Abad D., Hernández A., Carbonell P., Letón R., Robledo M., Rodríguez-Antona C., Perea J., Urioste M., Alonso M.Á., Andrés R., Arévalo S., del Mar Arias M., Balmaña J., Beristain E., Blanco I., Boronat M., Brunet J., Cózar M.V., del Campo M., Díaz A., Gabau E., Barcina M.J., González M., Guitart M., Hernán I., Hernández H.S., Hernando S., Lacambra C., Lasa A., Lastra E., Llort G., del Rosario Marín M., Marrupe D., Martínez F., Martínez V., Martorell L., Orera M., Pedrinaci S., Pérez P., Pineda M., Plasencia A.M., Cajal T.R., Robles L., Rodà D., Rodríguez N., Rosell J., Sáez R., Salvat M., Sánchez A., Santana A., Soto J.L., Toll A., Tuneu A., Vázquez C.. Considerations on diagnosis and surveillance measures of PTEN hamartoma tumor syndrome: clinical and genetic study in a series of Spanish patients. Orphanet Journal of Rare Diseases. 2022; 17(1)DOI:10.1186/s13023-021-02079-7. PMID:35227301. IF:3.700(Q2/4D).

01/01/2022 Peripheral Inflammatory Indexes Neutrophil/Lymphocyte Ratio (NLR) and Red Cell Distribution Width (RDW) as Prognostic Biomarkers in Advanced Solitary Fibrous Tumour (SFT) Treated with Pazopanib

Hidalgo-Ríos S., Carrillo-García J., Moura D.S., Stacchiotti S., López-Pousa A., Redondo A., Italiano A., Gutiérrez A., Grignani G., Hindi N., López-Guerrero J.-A., Muro X.G.D., Trufero J.M., Palmerini E., García A.S., Bernabeu D., Le Cesne A., Casali P.G., Blay J.-Y., Cruz Jurado J., Martin-Broto J.. Peripheral Inflammatory Indexes Neutrophil/Lymphocyte Ratio (NLR) and Red Cell Distribution Width (RDW) as Prognostic Biomarkers in Advanced Solitary Fibrous Tumour (SFT) Treated with Pazopanib. Cancers. 2022; 14(17)DOI:10.3390/cancers14174186. PMID:36077723. IF:5.200(Q2/3D).

01/01/2022 Recent therapeutic advances in urothelial carcinoma: A paradigm shift in disease management

Bellmunt J., Valderrama B.P., Puente J., Grande E., Bolós M.V., Lainez N., Vázquez S., Maroto P., Climent M.Á., Garcia del Muro X., Arranz J.Á., Durán I.. Recent therapeutic advances in urothelial carcinoma: A paradigm shift in disease management. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY. 2022; 174DOI:10.1016/j.critrevonc.2022.103683. PMID:35439541. IF:6.200(Q1/3D).

01/01/2022 Cell Senescence-Related Pathways Are Enriched in Breast Cancer Patients With Late Toxicity After Radiotherapy and Low Radiation-Induced Lymphocyte Apoptosis

Aguado-Flor E., Fuentes-Raspall M.J., Gonzalo R., Alonso C., Ramón y Cajal T., Fisas D., Seoane A., Sánchez-Pla Á., Giralt J., Díez O., Gutiérrez-Enríquez S.. Cell Senescence-Related Pathways Are Enriched in Breast Cancer Patients With Late Toxicity After Radiotherapy and Low Radiation-Induced Lymphocyte Apoptosis. Frontiers in Oncology. 2022; 12DOI:10.3389/fonc.2022.825703. PMID:35686103. IF:4.700(Q2/4D).

01/01/2022 Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non-Small-Cell Lung Cancer (NADIM phase II trial)

Provencio M., Serna-Blasco R., Nadal E., Insa A., García-Campelo M.R., Casal Rubio J., Dómine M., Majem M., Rodríguez-Abreu D., Martínez-Martí A., De Castro Carpeño J., Cobo M., López Vivanco G., Del Barco E., Bernabé Caro R., Viñolas N., Barneto Aranda I., Viteri S., Pereira E., Royuela A., Calvo V., Martín-López J., García-García F., Casarrubios M., Franco F., Sánchez-Herrero E., Massuti B., Cruz-Bermúdez A., Romero A.. Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non-Small-Cell Lung Cancer (NADIM phase II trial). JOURNAL OF CLINICAL ONCOLOGY. 2022; 71DOI:10.1200/JCO.21.02660. PMID:35576508. IF:45.300(Q1/1D).

01/01/2022 Durvalumab consolidation in patients with unresectable stage III non-small cell lung cancer with driver genomic alterations

Riudavets M., Auclin E., Mosteiro M., Dempsey N., Majem M., Lobefaro R., López-Castro R., Bosch-Barrera J., Pilotto S., Escalera E., Tagliamento M., Mosquera J., Zalcman G., Aboubakar-Nana F., Ponce S., Dal Maso A., Spotti M., Mielgo-Rubio X., Mussat E., Reyes R., Benítez J.-C., Lupinacci L., Duchemann B., De Giglio A., Blaquier J., Audigier-Valette C., Scheffler M., Nadal E., Lopes G., Signorelli D., Garcia-Campelo R., Menis J., Bluthgen V., Campayo M., Recondo G., Besse B., Planchard D., Mezquita L.. Durvalumab consolidation in patients with unresectable stage III non-small cell lung cancer with driver genomic alterations. EUROPEAN JOURNAL OF CANCER. 2022; 167DOI:10.1016/j.ejca.2022.02.014. PMID:35307254. IF:8.400(Q1/2D).

01/01/2022 Alectinib after failure to crizotinib in patients with ALK-positive non-small cell lung cancer: results from the Spanish early access program

Bernabé-Caro R., Garrido P., García-Campelo R., Palmero R., Artal Á., Bayona C., Rodríguez-Abreu D., López-Brea M., Paredes A., Vicente D., Torres J.M.S., Majem M., Diz P., Gordo R., Coca M., de Castro J.. Alectinib after failure to crizotinib in patients with ALK-positive non-small cell lung cancer: results from the Spanish early access program. Oncotarget. 2022; 13(1)DOI:10.18632/oncotarget.28244. PMID:. IF:(Q/D).

01/01/2022 Gastrointestinal stromal tumours: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up ?

Casali P.G., Blay J.Y., Abecassis N., Bajpai J., Bauer S., Biagini R., Bielack S., Bonvalot S., Boukovinas I., Bovee J.V.M.G., Boye K., Brodowicz T., Buonadonna A., De Álava E., Dei Tos A.P., Del Muro X.G., Dufresne A., Eriksson M., Fedenko A., Ferraresi V., Ferrari A., Frezza A.M., Gasperoni S., Gelderblom H., Gouin F., Grignani G., Haas R., Hassan A.B., Hindi N., Hohenberger P., Joensuu H., Jones R.L., Jungels C., Jutte P., Kasper B., Kawai A., Kopeckova K., Krákorová D.A., Le Cesne A., Le Grange F., Legius E., Leithner A., Lopez-Pousa A., Martin-Broto J., Merimsky O., Messiou C., Miah A.B., Mir O., Montemurro M., Morosi C., Palmerini E., Pantaleo M.A., Piana R., Piperno-Neumann S., Reichardt P., Rutkowski P., Safwat A.A., Sangalli C., Sbaraglia M., Scheipl S., Schöffski P., Sleijfer S., Strauss D., Strauss S.J., Hall K.S., Trama A., Unk M., van de Sande M.A.J., van der Graaf W.T.A., van Houdt W.J., Frebourg T., Gronchi A., Stacchiotti S., EURACAN and GENTURIS. Gastrointestinal stromal tumours: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up ?. ANNALS OF ONCOLOGY. 2022; 33(1)DOI:10.1016/j.annonc.2021.09.005. PMID:34560242. IF:50.500(Q1/1D).

01/01/2022 Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy – results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial

Peters S., Pujol J.-L., Dafni U., Dómine M., Popat S., Reck M., Andrade J., Becker A., Moro-Sibilot D., Curioni-Fontecedro A., Molinier O., Nackaerts K., Insa Mollá A., Gervais R., López Vivanco G., Madelaine J., Mazieres J., Faehling M., Griesinger F., Majem M., González Larriba J.L., Provencio Pulla M., Vervita K., Roschitzki-Voser H., Ruepp B., Mitchell P., Stahel R.A., Le Pechoux C., De Ruysscher D., Stahel R., Hiltbrunner A., Pardo-Contreras M., Gasca-Ruchti A., Giacomelli N., Kammler R., Marti N., Pfister R., Piguet A.C., Roux S., Troesch S., Schneider M., Schweri R., Zigomo I., Tsourti Z., Zygoura P., Tsouprou S., Kassapian M., Dimopoulou G., Andriakopoulou C., Morin F., Amour E., Mariaule G., Archirel N., Fernandez M., Pereira E., Benito L., Lopez K., Hernández A., Chinchen S., Jurkovic H., Livingstone A., Mitchell J., Walker M., Ng S., Steer C., Briscoe K., Saqib A., Abdi E., Houghton B., O'Byrne K., Chittajallu B.R., Hughes B.G., Black A., Werner H., Zalcman G., Vaylet F., Merle P., Monnet I., Girard N., Souquet P.-J., Barlesi F., Debieuvre D., Senellart H., Poudenx M., Dixmier A., Pouessel D., Cadranel J., Lena H., Quoix E., Friard S., Audigier-Valette C., Pichon E., Kokowski K., Kirchen H., Tufman A., De-Colle C., de Langen J., Insa A., Massutí B., Pulla M.P., Aix S.P., Villanueva N., Vivanco G.L., Franks K., Califano R.. Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy – results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial. ANNALS OF ONCOLOGY. 2022; 33(1)DOI:10.1016/j.annonc.2021.09.011. PMID:34562610. IF:50.500(Q1/1D).

01/12/2021 Efficacy of nintedanib plus docetaxel in patients with refractory advanced epidermal growth factor receptor mutant lung adenocarcinoma

Riudavets, M, Bosch-Barrera, J, Cabezon-Gutierrez, L, Tain, PD, Hernandez, A, Alonso, M, Blanco, R, Galvez, E, Insa, A, Mielgo, X, Moran, T, Ponce, S, Roa, D, Sanchez, JM, Majem, M. Efficacy of nintedanib plus docetaxel in patients with refractory advanced epidermal growth factor receptor mutant lung adenocarcinoma. Clinical & Translational Oncology. 2021; 23(12)DOI:10.1007/s12094-021-02661-2. PMID:34292495. IF:3.340(Q3/7D).

01/09/2021 Uncommon and peculiar soft tissue sarcomas: Multidisciplinary review and practical recommendations for diagnosis and treatment. Spanish group for Sarcoma research (GEIS - GROUP). Part I

Martinez-Trufero, J, Jurado, JC, Gomez-Mateo, MC, Bernabeu, D, Floria, LJ, Lavernia, J, Sebio, A, del Muro, XG, Alvarez, R, Correa, R, Hernandez-Leon, CN, Marquina, G, Hindi, N, Redondo, A, Martinez, V, Asencio, JM, Mata, C, Morales, CMV, Martin-Broto, J. Uncommon and peculiar soft tissue sarcomas: Multidisciplinary review and practical recommendations for diagnosis and treatment. Spanish group for Sarcoma research (GEIS - GROUP). Part I. CANCER TREATMENT REVIEWS. 2021; 99DOI:10.1016/j.ctrv.2021.102259. PMID:34311246. IF:13.608(Q1/1D).

01/09/2021 Uncommon and peculiar soft tissue sarcomas: Multidisciplinary review and practical recommendations. Spanish Group for Sarcoma research (GEIS -GROUP). Part II

Martinez-Trufero, J, Jurado, JC, Hernandez-Leon, CN, Correa, R, Asencio, JM, Bernabeu, D, Alvarez, R, Hindi, N, Mata, C, Marquina, G, Martinez, V, Redondo, A, Floria, LJ, Gomez-Mateo, MC, Lavernia, J, Sebio, A, del Muro, XG, Martin-Broto, J, Valverde-Morales, C. Uncommon and peculiar soft tissue sarcomas: Multidisciplinary review and practical recommendations. Spanish Group for Sarcoma research (GEIS -GROUP). Part II. CANCER TREATMENT REVIEWS. 2021; 99DOI:10.1016/j.ctrv.2021.102260. PMID:34340159. IF:13.608(Q1/1D).

01/05/2025 Real-world treatment patterns, survival outcomes, and health care resource utilization for locally advanced or metastatic urothelial carcinoma in Spain

Puente, J, Pinto, A, Mendez-Vidal, MJ, del Muro, XG, Maroto, P, Vazquez, S, Luque-Caro, R, Anido, U, Strunz-McKendry, T, Upadhyay, A, Montes, J, Nuñez, AO, Portela, JG, Castellano, D. Real-world treatment patterns, survival outcomes, and health care resource utilization for locally advanced or metastatic urothelial carcinoma in Spain. Clinical & Translational Oncology. 2025; 27(5)DOI:10.1007/s12094-024-03734-8. PMID:39365365. IF:2.500(Q3/6D).

01/01/2025 Nivolumab and sunitinib in patients with advanced bone sarcomas: A multicenter, single-arm, phase 2 trial

Palmerini, E, Pousa, AL, Grignani, G, Redondo, A, Hindi, N, Provenzano, S, Sebio, A, Martin, JAL, Valverde, C, Trufero, JM, Gutierrez, A, de Alava, E, Gomez, MPA, D'Ambrosio, L, Collini, P, Bazzocchi, A, Moura, DS, Ibrahim, T, Stacchiotti, S, Broto, JM. Nivolumab and sunitinib in patients with advanced bone sarcomas: A multicenter, single-arm, phase 2 trial. CANCER. 2025; 131(1)DOI:10.1002/cncr.35628. PMID:39540661. IF:5.100(Q1/3D).

01/12/2024 Pharmacogenetics of Neoadjuvant MAP Chemotherapy in Localized Osteosarcoma: A Study Based on Data from the GEIS-33 Protocol

Salazar, J, Arranz, MJ, Martin-Broto, J, Bautista, F, Martínez-García, J, Martínez-Trufero, J, Vidal-Insua, Y, Echebarria-Barona, A, Díaz-Beveridge, R, Valverde, C, Luna, P, Vaz-Salgado, MA, Blay, P, Alvarez, R, Sebio, A. Pharmacogenetics of Neoadjuvant MAP Chemotherapy in Localized Osteosarcoma: A Study Based on Data from the GEIS-33 Protocol. Pharmaceutics. 2024; 16(12)DOI:10.3390/pharmaceutics16121585. PMID:39771563. IF:5.500(Q1/1D).

01/11/2024 Walking one hour per day and the derived neutrophil-to-lymphocyte ratio are associated with outcome in palliative second-line immunotherapy for patients with recurrent and/or metastatic squamous cell carcinoma of head and neck

Caballero-Borrego, M, Piedra, A, Gallego, O, López-Pousa, A, Castillo, P, Navarrete, P, Prat, A, Grau, JJ. Walking one hour per day and the derived neutrophil-to-lymphocyte ratio are associated with outcome in palliative second-line immunotherapy for patients with recurrent and/or metastatic squamous cell carcinoma of head and neck. Brazilian Journal of Otorhinolaryngology. 2024; 90(6)DOI:10.1016/j.bjorl.2024.101493. PMID:39205362. IF:1.800(Q2/4D).

01/11/2024 Eftilagimod Alpha (a Soluble LAG-3 Protein) Combined With Pembrolizumab in Second-Line Metastatic NSCLC Refractory to Anti-Programmed Cell Death Protein 1/Programmed Death-Ligand 1-Based Therapy: Final Results from a Phase 2 Study

Krebs, MG, Forster, M, Majem, M, Peguero, J, Iams, W, Clay, T, Roxburgh, P, Doger, B, Bajaj, P, Barba, A, Perera, S, Mueller, C, Triebel, F. Eftilagimod Alpha (a Soluble LAG-3 Protein) Combined With Pembrolizumab in Second-Line Metastatic NSCLC Refractory to Anti-Programmed Cell Death Protein 1/Programmed Death-Ligand 1-Based Therapy: Final Results from a Phase 2 Study. Jto Clinical And Research Reports. 2024; 5(11)DOI:10.1016/j.jtocrr.2024.100725. PMID:39403626. IF:(Q/D).

01/11/2024 Perioperative chemotherapy and nivolumab in non-small-cell lung cancer (NADIM): 5-year clinical outcomes from a multicentre, single-arm, phase 2 trial

Provencio, M, Nadal, E, Insa, A, Campelo, RG, Casal, J, Dómine, M, Massuti, B, Majem, M, Rodríguez-Abreu, D, Martínez-Marti, A, de Castro, J, de Antonio, DG, Macia, I, Figueroa, S, Vago, LF, Calvo, V, Palmero, R, Sierra-Rodero, B, Martínez-Toledo, C, Molina-Alejandre, M, Serna-Blasco, R, Romero, A, Cruz-Bermúdez, A. Perioperative chemotherapy and nivolumab in non-small-cell lung cancer (NADIM): 5-year clinical outcomes from a multicentre, single-arm, phase 2 trial. LANCET ONCOLOGY. 2024; 25(11)DOI:10.1016/S1470-2045(24)00498-4. PMID:39419061. IF:35.900(Q1/1D).

01/11/2024 Recommendations on the Treatment of Metastatic Hormone-Sensitive Prostate Cancer: Patient Selection

Borque-Fernando, A, Zapatero, A, Manneh, R, Alonso-Gordoa, T, Couñago, F, Domínguez-Esteban, M, López-Valcárcel, M, Rodríguez-Antolín, A, Sala-González, N, Sanmamed, N, Maroto, P. Recommendations on the Treatment of Metastatic Hormone-Sensitive Prostate Cancer: Patient Selection. Actas Urologicas Espanolas. 2024; 48(9)DOI:10.1016/j.acuro.2024.03.002. PMID:38740263. IF:1.200(Q3/7D).

01/11/2024 Longitudinal Analyses of Circulating Tumor DNA for the Detection of EGFR Mutation-Positive Advanced NSCLC Progression During Treatment: Data From FLAURA and AURA3

Gray, JE, Markovets, A, Reungwetwattana, T, Majem, M, Nogami, N, Peled, N, Lee, JS, Cho, BC, Chewaskulyong, B, John, T, Han, JY, Sebastian, M, Todd, A, Rukazenkov, Y, Barrett, C, Chmielecki, J, Lee, SM, Ramalingam, SS, Hartmaier, R. Longitudinal Analyses of Circulating Tumor DNA for the Detection of EGFR Mutation-Positive Advanced NSCLC Progression During Treatment: Data From FLAURA and AURA3. Journal of Thoracic Oncology. 2024; 19(11)DOI:10.1016/j.jtho.2024.07.008. PMID:39029876. IF:20.800(Q1/1D).

01/11/2024 Development of a prognostic model to predict 90-day mortality in hospitalised cancer patients (PROMISE tool): a prospective observational study

Mirallas, O, Martin-Cullell, B, Navarro, V, Vega, KS, Recuero-Borau, J, Gómez-Puerto, D, López-Valbuena, D, de Torres, CS, Andurell, L, Pedrola, A, Berché, R, Palmas, F, Ucha, JM, Villacampa, G, Rezqallah, A, Sanz-Beltran, J, Bach, R, Bueno, S, Viaplana, C, Molina, G, Hernando-Calvo, A, Aguilar-Company, J, Roca, M, Muñoz-Couselo, E, Martínez-Martí, A, Alonso, A, Eremiev, S, Macarulla, T, Oaknin, A, Saura, C, Élez, E, Felip, E, Peñuelas, A, Burgos, R, Pardo, PG, Garralda, E, Tabernero, J, Serradell, S, Servitja, S, Paez, D, Dienstmann, R, Carles, J. Development of a prognostic model to predict 90-day mortality in hospitalised cancer patients (PROMISE tool): a prospective observational study. Lancet Regional Health-Europe. 2024; 46DOI:10.1016/j.lanepe.2024.101063. PMID:39529819. IF:13.000(Q1/1D).

17/10/2024 P25.03.B RWD OF IDH MUTANT GLIOMAS IN SPAIN, A RETSINE - GEINO STUDY

Mazariegos, M, Girones, R, Del Barco, S, Garcia, A, Velilla, G, Hernandez, A, Alonso, M, Ferreira, L, Luque, N, Fernández,, Quintanar, T, Peralta, S, Ceballos,, Iza, E, Sanchez, M, Martín, EP, Casado, EA, Mazarico, J, Duran, G, Alvarez, P, Ayala, P, Gallego, O, Sarabia, R, de las Penas, R, Nuñez,, Morilla,, Cunquero, A, Cheverria, N, Moya,, Vaz, M, Luque, R, Esteve, A, Pineda, E. P25.03.B RWD OF IDH MUTANT GLIOMAS IN SPAIN, A RETSINE - GEINO STUDY. NEURO-ONCOLOGY. 2024; 26DOI:10.1093/neuonc/noae144.446. PMID:. IF:13.400(Q1/1D).

06/10/2024 Impact of COVID-19 infection on genitourinary cancer management. SOGUG-COVID-19: A spanish, multicenter, observational study

Vidal, N, Climent, MA, Pérez, S, Méndez-Vidal, MJ, Anguera, G, Salas, IM, Gallardo, E, Cuéllar-Rivas, MA, Molina-Cerrillo, J, Martín, A, Rodriguez-Vida, A, Casado, EA, Gonzalez, M, Domènech, M, Kareaga, MM, Calvo, OF, Guzmán, JCV, Estévez, SV, Gonzàlez-del-Alba, A, Puente, J. Impact of COVID-19 infection on genitourinary cancer management. SOGUG-COVID-19: A spanish, multicenter, observational study. Clinical & Translational Oncology. 2024; DOI:10.1007/s12094-024-03744-6. PMID:39369361. IF:2.500(Q3/6D).

01/10/2024 Dual mTOR1/2 Inhibitor Sapanisertib (FTH-003/TAK-228) in Combination With Weekly Paclitaxel in Patients With Previously Treated Metastatic Urothelial Carcinoma: A Phase II Open-Label Study

Bellmunt, J, Maroto, P, Bonfill, T, Vazquez, F, Perez-Gracia, JL, Juanpere, N, Hernandez-Prat, A, Hernandez-Llodra, S, Rovira, A, Juan, OS, Rodriguez-Vida, A. Dual mTOR1/2 Inhibitor Sapanisertib (FTH-003/TAK-228) in Combination With Weekly Paclitaxel in Patients With Previously Treated Metastatic Urothelial Carcinoma: A Phase II Open-Label Study. Clinical Genitourinary Cancer. 2024; 22(5)DOI:10.1016/j.clgc.2024.102123. PMID:38905731. IF:2.700(Q2/3D).

01/10/2024 The impact of previous therapy on overall-survival in registration clinical trials for 1st line metastatic breast cancer a systemic review

Abu Remilah, A, Krayim, B, Amir, E, Tibau, A, Robson, ME, Abuhadra, N, Chen, Y, Shepshelovich, D, Goldvaser, H. The impact of previous therapy on overall-survival in registration clinical trials for 1st line metastatic breast cancer a systemic review. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY. 2024; 202DOI:10.1016/j.critrevonc.2024.104455. PMID:39067779. IF:5.600(Q1/2D).

01/10/2024 Patient-reported outcomes in CodeBreaK 200: Sotorasib versus docetaxel for previously treated advanced NSCLC with KRAS G12C mutation

Waterhouse, DM, Rothschild, S, Dooms, C, Mennecier, B, Bozorgmehr, F, Majem, M, Heuvel, MHV, Linardou, H, Cho, BC, Roberts-Thomson, R, Tanaka, K, Blais, N, Schvartsman, G, Hansen, KH, Chmielewska, I, Forster, MD, Giannopoulou, C, Stollenwerk, B, Obiozor, CC, Wang, Y, Novello, S. Patient-reported outcomes in CodeBreaK 200: Sotorasib versus docetaxel for previously treated advanced NSCLC with KRAS G12C mutation. LUNG CANCER. 2024; 196DOI:10.1016/j.lungcan.2024.107921. PMID:39303400. IF:4.400(Q1/2D).

01/10/2024 Prognostic Laboratory Parameters in Imfirst: Atezolizumab Plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer

de Castro, J, Dols, MC, Gómez, MD, Vega, AM, Aix, SP, Arriola, E, Carcereny, E, Majem, M, Vence, GH, González, EE, Pradera, JF, Granados, ALO, Morales, MG, Sureda, BM, Núñez, NF, Provencio, M, González-Mancha, N, Fajardo, CA, Lerones, N, Campelo, RG. Prognostic Laboratory Parameters in Imfirst: Atezolizumab Plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. Journal of Thoracic Oncology. 2024; 19(10)DOI:. PMID:. IF:20.800(Q1/1D).

01/10/2024 Association of Pathologic Regression with EFS in the KEYNOTE-671 Study of Perioperative Pembrolizumab for Early-Stage NSCLC

Jones, DR, Wakelee, H, Spicer, JD, Liberman, M, Kato, T, Tsuboi, M, Lee, SH, Wang, W, Chen, H, Dooms, C, Majem, M, Eigendorff, E, Martinengo, GL, Bylicki, O, Huang, HC, Novello, S, Jensen, E, Keller, SM, Samkari, A, Kalhor, N. Association of Pathologic Regression with EFS in the KEYNOTE-671 Study of Perioperative Pembrolizumab for Early-Stage NSCLC. Journal of Thoracic Oncology. 2024; 19(10)DOI:. PMID:. IF:20.800(Q1/1D).

01/10/2024 An Evidence-Driven Approach to Optimizing Clinical, Operational, And Economic Value in the Lung Cancer Care Pathway

Majem, M, Sullivan, IG, Torrego, A, Surrallés, J, Purdy, J, Carmona, MA, Dunsford, H, Wubs, M. An Evidence-Driven Approach to Optimizing Clinical, Operational, And Economic Value in the Lung Cancer Care Pathway. Journal of Thoracic Oncology. 2024; 19(10)DOI:. PMID:. IF:20.800(Q1/1D).